The Prognosis of Acute Myocardial Infarction in Xinjiang

Study Overview
=================
Brief Summary
-----------------
This study is to build a Xinjiang people registry and surveillance system for acute myocardial infarction(AMI) information about patient's basic information, patient characteristics, diagnostic test mode, the program of treatment and hospitalization outcomes including mortality, treatment complications, the cost of hospitalization and follow-up events (death, major adverse cardiac events, stroke, heart failure) of AMI patients; And to propose scientific precaution strategies aimed to prevent effectively from the incidence of AMI; And to optimize the management and outcomes of AMI patients through implementation of guideline recommendations in clinical practice, and to perform analyses and development of effective treatment strategies and predictive models of clinical ourtcomes.

Detailed Description
-----------------
The aim of the study is to establish the platform for surveillance, clinical research and translational medicine in Xinjiang , designed to provide a foundation for future quality improvement and research as well as facilitate efforts to improve the quality of AMI patient care , translate research into improved care for patients and thus decrease morbidity and mortality associated with AMI.

Official Title
-----------------
The Characteristics and Clinical Outcomes of Acute Myocardial Infarction: A Prospective Cohort Study

Conditions
-----------------
Acute Myocardial Infarction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acute myocardial infarction patients in hospitalized of The First Affiliated Hospital of Xinjiang Medical (include diagnosed acute ST-elevation or non ST-elevation myocardial infarction).Diagnosis criteria must meet Universal Definition for AMI (2012). Exclusion Criteria: Combined with severe valvular heart disease; Combined with severe congenital heart disease; Combined hyperthyroidism, anemia and other high-powered heart disease; With pulmonary heart disease; With hypertrophic obstructive cardiomyopathy; Severe hypotension (SBP <90mmHg or DBP <60mmHg at enrollment); Uncontrolled hypertension (SBP> 160 mmHg before PCI, and / or DBP> 100 mmHg); Liver dysfunction (defined as ALT or total bilirubin is greater than the normal upper limit of 3 times); Renal insufficiency (defined as serum creatinine greater than 1.5 times the normal upper limit); High-risk bleeding patients, such as thrombocytopenia, blood diseases and other diseases; active peptic ulcer and skin ulcers; A patient who is allergic to clopidogrel, tegrellol, or aspirin; Patients with a history of cardiogenic shock within two weeks; pregnant and lactating women, during treatment can not be strict contraception of women of childbearing age; In the past 3 months participated in other clinical researchers; Persons who do not have legal or legal competence; Any condition that the investigator considers unsuitable for participation in the clinical study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| AMI patients with treatment of PCI<br>All the patiets treat with PCI were enrolled and recorded the clinical characteristic and outcomes during the follow-up period. | |
| Medication<br>All the patiets treat with medication (standard secondary prevention) without PCI were enrolled and recorded the clinical characteristic and outcomes during the follow-up period. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Death | All-cause mortality, Cardiac mortality | At least 6 months, Up to 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major adverse cardiovascular events (MACE) | Recurrent myocardial infarction，ST，Revascularization，Angina, Stroke | At least 6 months, Up to 5 years | 
| bleeding events | bleeding >_ grade 2 according to BARC criteria | At least 6 months, Up to 5 years | 
| Re-MI | MI was defined in accordance with the universal definition proposed in 2007 | At least 6 months, Up to 5 years | 
| Stent thrombosis | according to the Academic Research Consortium criteria | At least 6 months, Up to 5 years | 
| Stroke | Stroke was defined as focal loss of neurological function caused by an ischaemic or haemorrhagic event, with residual symptoms lasting at least 24 hours or leading to death | At least 6 months, Up to 5 years | 
| Urgent revascularization | revascularization with or without changes in the ST segment or T wave or elevated biomarker levels | At least 6 months, Up to 5 years | 
| Cardiac death | Deaths were considered cardiac unless an unequivocal, noncardiac cause was established | At least 6 months, Up to 5 years |